ERBB2 and breast neoplasm: Similarly, elevated deposition of laminin-5 in breast tumors conferred resistance to anti-HER2 compounds (lapatinib and the HER2 monoclonal antibody trastuzumab), through the activation of an integrin-CD151-FAK mediated pathway [49].